EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial

Megan O Bensignor iD, Carolyn T Bramante iD, Eric M Bomberg iD, Claudia K Fox iD, Paula M Hale, Aaron S Kelly, Rashmi Mamadi, Nandana Prabhu, Nina M Harder-Lauridsen, Amy C Gross iD

Pediatric Obesity · 2023

DOI: 10.1111/ijpo.13061 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Obesity, 2023. Verfasst von Megan O Bensignor und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Diabetes Mellitus, Type 2, Pediatric Obesity. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As childhood obesity prevalence increases, determining which patients respond to anti‐obesity medications would strengthen personalized approaches to obesity treatment. In the SCALE Teens trial among pubertal adolescents with obesity (NCT02918279), liraglutide 3.0 mg (or maximum tolerated dose) significantly reduced body mass index (BMI) standard deviation score on average versus placebo. That said, liraglutide effects on BMI reduction varied greatly among adolescents, similar to adults.

Objectives

To identify post hoc characteristics predictive of achieving ≥5% and ≥10% BMI reductions at 56 weeks with liraglutide versus placebo in adolescents from the SCALE Teens trial.

Methods

Logistic regression analysis was performed in 251 adolescents treated with liraglutide ( n = 125) or placebo ( n = 126) for 56 weeks. Baseline characteristics (selected a priori) included sex, race, ethnicity, age, Tanner (pubertal) stage, glycemic status (hyperglycemia [type 2 diabetes/prediabetes] vs. normoglycemia), obesity category (Class II/III vs. I), severity of depression symptoms (Patient Health Questionnaire‐9), and weight variability (weight fluctuations over time). The effects of early responder status (≥4% BMI reduction at week 16) on week 56 response were assessed using descriptive statistics.

Results

Baseline characteristics did not affect achievement of ≥5% and ≥10% BMI reductions at week 56 in adolescents treated with liraglutide. Further, there was no association between weight variability and BMI reduction. Early liraglutide responders appeared to have greater BMI and body weight reductions at week 56 compared with early non‐responders.

Conclusions

This secondary analysis suggests that adolescents with obesity may experience significant BMI reductions after 56 weeks of liraglutide treatment, regardless of their sex, race, ethnicity, age, pubertal stage, glycemic status, obesity category, severity of depression symptoms, or weight variability. Early response may predict greater week 56 response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsDiabetes Mellitus, Type 2Pediatric ObesityAdolescentAdultChildHumansLiraglutideWeight LossTreatment Outcome

Stichwörter der Autor:innen

anti-agentsglucagon-like peptide-1 receptor agonistsliraglutideobesitypaediatric obesityweight management

Substanzen

Anti-Obesity AgentsLiraglutide

Autor:innen und Institutionen

  • Department of Pediatrics, Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
  • Clinical Development, Medical & Regulatory Affairs, Novo Nordisk Inc., Plainsboro, New Jersey, USA.
  • Global Medical Affairs, Novo Nordisk, Bangalore, India.
  • Biostatistics, Novo Nordisk, Bangalore, India.
  • Medical and Science, Novo Nordisk A/S, Søborg, Denmark.

ORCID-Profile: Megan O Bensignor, Carolyn T Bramante, Eric M Bomberg, Claudia K Fox, Amy C Gross

Förderung

  • NIDDK NIH HHS
  • Novo Nordisk

Zitieren

APA

Bensignor, M. O., Bramante, C. T., Bomberg, E. M., Fox, C. K., Hale, P. M., Kelly, A. S., Mamadi, R., Prabhu, N., Harder-Lauridsen, N. M., & Gross, A. C. (2023). Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial. Pediatric Obesity. https://doi.org/10.1111/ijpo.13061

Vancouver

Bensignor MO, Bramante CT, Bomberg EM, Fox CK, Hale PM, Kelly AS, et al. Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial. Pediatric Obesity. 2023. doi:10.1111/ijpo.13061

BibTeX
@article{Bensignor2023,
  author = {Bensignor, Megan O and Bramante, Carolyn T and Bomberg, Eric M and Fox, Claudia K and Hale, Paula M and Kelly, Aaron S and Mamadi, Rashmi and Prabhu, Nandana and Harder-Lauridsen, Nina M and Gross, Amy C},
  title = {Evaluating potential predictors of weight loss response to liraglutide in adolescents with obesity: A post hoc analysis of the randomized, placebo‐controlled SCALE Teens trial},
  journal = {Pediatric Obesity},
  year = {2023},
  doi = {10.1111/ijpo.13061}
}
Kostenlos starten →